Saturday 17 October 2026
Export BIO’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
353.70
11.12
−3.05%
Follow BIO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
35.25 | 45.62 | 10.84 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.03 | 2.90 | 3.20 | 2.95 | |
P/FCF ratio |
22.11 | 20.91 | 21.93 | 22.27 | |
P/Operating CF |
79.56 | 69.51 | 50.09 | 62.44 | |
P/B ratio |
1.09 | 1.10 | 1.11 | 1.12 | |
Price to Tangible BV |
1.22 | 1.23 | 1.23 | 1.31 | |
EV/Sales |
2.87 | 2.76 | 3.07 | 2.87 | |
EV/EBITDA |
140.08 | 124.19 | 167.85 | 32.66 | |
EV/Operating CF |
15.10 | 14.02 | 14.89 | 14.92 | |
EV/FCF |
20.95 | 19.90 | 21.03 | 21.64 | |
Quick Ratio |
2.14 | 2.17 | 3.87 | 3.61 | |
Current Ratio |
3.14 | 3.21 | 5.62 | 5.44 | |
Net Debt/EBITDA |
(5.71) | (10.60) | 2.84 | (3.31) | |
Debt/Assets |
11.74% | 12.29% | 11.37% | 12.40% | |
Debt/Equity |
0.17 | 0.18 | 0.16 | 0.18 | |
Asset Turnover |
0.25 | 0.27 | 0.26 | 0.25 | |
Operating CF/Net income |
0.27 | (0.21) | 0.23 | (0.35) | |
Capex/Depreciation |
0.00 | 0.00 | (0.28) | 0.00 | |
Interest Coverage |
6.00 | 2.77 | (9.83) | 5.31 | |
Research and Development Expense of Revenue |
9.40% | 0.00% | 0.00% | 10.92% | |
Selling, General and Administrative Expense of Revenue |
32.57% | 35.87% | 31.88% | 31.67% | |
Intangible Assets out of Total Assets |
0.07 | 0.08 | 0.07 | 0.10 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 8.37% | 0.00% | |
Graham Net Nets |
(0.01) | 0.00 | (0.03) | (0.02) | |
Graham Number |
224.21 | 186.92 | 414.65 | 0.00 | |
Earnings Yield |
2.84% | 2.19% | 9.22% | (8.67%) | |
Free Cash Flow Yield |
4.52% | 4.78% | 4.56% | 4.49% | |
Revenue per Share |
24.34 | 21.96 | 25.43 | 24.25 | |
Operating CF per Share |
3.69 | 4.01 | 6.05 | 4.49 | |
Capex per Share |
(1.20) | (1.11) | (1.68) | (1.18) | |
Free Cash Flow per Share |
2.49 | 2.90 | 4.37 | 3.31 | |
Cash per Share |
60.51 | 58.04 | 56.51 | 52.69 | |
Shareholders Equity per Share |
268.22 | 254.15 | 273.40 | 250.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
268.22 | 254.15 | 273.40 | 250.22 | |
Free Cash Flow |
66.60 | 78.20 | 119.10 | 89.20 | |
Working Capital |
2,059.20 | 2,025.10 | 2,389.20 | 2,319.70 | |
Capital Expenditures |
(32.10) | (29.90) | (45.80) | (31.70) | |
Net Current Asset Value |
(57.60) | 3.40 | (216.70) | (117.60) | |
EV/EBIT |
140.08 | 124.19 | 167.85 | 32.66 | |
Capex to Sales |
0.05 | 0.05 | 0.07 | 0.05 | |
Price to Operating Income |
147.89 | 130.46 | 175.01 | 33.63 | |
| Other line items | |||||
Average Receivables |
455.85 | 425.45 | 456.55 | 463.32 | |
Average Payables |
141.40 | 135.50 | 125.65 | 125.49 | |
Average Inventory |
789.70 | 780.30 | 750.35 | 793.74 | |
Average Assets |
10,233.05 | 9,658.45 | 9,970.30 | 10,149.94 | |
Average Common Equity |
7,151.30 | 6,765.35 | 7,011.45 | 7,112.33 |
Columns are period end dates